BEROMUN (Tasonermin)

What Is BEROMUN and What Is It Used For?

BEROMUN (tasonermin) is a recombinant human tumor necrosis factor alpha-1a used in isolated limb perfusion (ILP) alongside melphalan for the treatment of irresectable soft tissue sarcoma of the limbs. It is designed to shrink tumors and allow limb-sparing surgery, avoiding the need for amputation.

BEROMUN contains the active substance tasonermin, which is a form of the naturally occurring cytokine tumor necrosis factor alpha (TNF-alpha). TNF-alpha plays a critical role in the body's immune response and has potent antitumor properties when delivered in high concentrations directly to tumors. However, because TNF-alpha causes severe toxicity when present in the systemic circulation at therapeutic doses, it can only be safely administered through a technique called isolated limb perfusion.

Soft tissue sarcomas are rare malignant tumors that arise in the connective tissues of the body, including muscle, fat, blood vessels, nerves, and tendons. When these tumors develop in the arms or legs and grow to a size or location that makes complete surgical removal impossible without amputation, BEROMUN offers an alternative approach. By temporarily isolating the blood supply of the affected limb and perfusing it with high concentrations of tasonermin and melphalan, physicians can achieve tumor shrinkage sufficient to allow subsequent limb-sparing surgery.

The European Medicines Agency (EMA) has approved BEROMUN for two specific indications. First, as an adjunct to surgery for soft tissue sarcoma of the limbs, intended to prevent or delay amputation. Second, in the palliative setting for irresectable soft tissue sarcoma of the limbs. In both cases, the drug is used as part of a multimodal treatment approach that includes surgery, and sometimes radiotherapy, coordinated by a multidisciplinary oncology team.

Clinical trials supporting the approval of BEROMUN demonstrated overall response rates of approximately 75-80% when tasonermin was combined with melphalan during isolated limb perfusion. Complete response rates were observed in approximately 18-20% of patients, and the limb salvage rate reached approximately 82-87%. These results were significantly better than those achieved with melphalan alone, which historically yielded response rates of only 50-55%.

What Should You Know Before Receiving BEROMUN?

BEROMUN should not be used in patients with significant cardiovascular disease, severe organ dysfunction, or during pregnancy. A thorough pre-treatment evaluation is essential, including assessment of cardiac function, liver and kidney status, and confirmation that the tumor is truly confined to the limb.

Contraindications

BEROMUN must not be administered in several clinical situations. Absolute contraindications include known hypersensitivity to tasonermin or any of the excipients, significant cardiovascular disease (including recent myocardial infarction, congestive heart failure, or significant arrhythmias), severe hepatic impairment, severe renal impairment, severe pulmonary disease, active peptic ulcer disease, and conditions where isolated limb perfusion cannot be safely performed.

Patients with a history of blood clotting disorders are also at elevated risk, as the isolated limb perfusion procedure itself and the pharmacological effects of TNF-alpha can both affect coagulation parameters. Similarly, patients with severe peripheral vascular disease may not be suitable candidates, as adequate vascular access and blood flow are essential requirements for the ILP procedure.

Before treatment, all patients must undergo comprehensive medical evaluation including echocardiography or cardiac imaging, complete blood count, liver function tests, renal function tests, and coagulation studies. Imaging studies to confirm that the sarcoma is confined to the limb and to rule out distant metastases are also mandatory, as ILP is a local treatment and is not appropriate for disseminated disease.

Warnings and Precautions

The most critical safety consideration with BEROMUN is the prevention of systemic leakage during isolated limb perfusion. Even small amounts of TNF-alpha entering the systemic circulation can cause a severe inflammatory response resembling septic shock. Continuous leak monitoring using radiolabeled albumin or similar techniques is mandatory throughout the procedure. If systemic leakage exceeds 10%, the perfusion must be stopped immediately and supportive measures initiated.

Compartment syndrome is a recognized complication of the ILP procedure and can occur in the perfused limb. This condition involves increased pressure within the muscle compartments of the limb, which can compromise blood flow and cause tissue damage. Close post-operative monitoring of the limb, including clinical assessment and pressure measurements if indicated, is essential for the first 48-72 hours after the procedure.

Hepatotoxicity has been reported following BEROMUN administration, even with minimal systemic leakage. Liver function tests should be monitored closely before, during, and after the procedure. In most cases, liver enzyme elevations are transient and resolve within 1-2 weeks, but severe hepatotoxicity requiring medical intervention has been reported in rare cases.

Cardiac monitoring is essential throughout the procedure and for at least 48 hours afterward. TNF-alpha has known cardiotoxic properties, and patients may experience arrhythmias, hypotension, or myocardial depression. An intensive care setting with continuous hemodynamic monitoring is required for the immediate post-operative period.

Pregnancy and Breastfeeding

BEROMUN is contraindicated during pregnancy. TNF-alpha is known to cross the placental barrier and could cause serious harm to the developing fetus. Women of childbearing potential must have a negative pregnancy test before treatment and must use effective contraception during and for a period after treatment as determined by their treating physician.

It is not known whether tasonermin is excreted in human breast milk. Due to the serious nature of the drug and the potential for adverse effects in the nursing infant, breastfeeding must be discontinued before treatment and should not be resumed until the drug has been fully cleared from the body. Patients should discuss the timing of resuming breastfeeding with their healthcare team.

How Does BEROMUN Interact with Other Drugs?

BEROMUN is always used in combination with melphalan during isolated limb perfusion. Due to its localized administration, systemic drug interactions are limited but can occur if there is leakage into the general circulation. Key interactions involve cardiotoxic agents, anticoagulants, and hepatotoxic drugs.

Because BEROMUN is administered via isolated limb perfusion rather than systemically, the potential for traditional drug-drug interactions is limited compared to conventional chemotherapy agents. However, the possibility of systemic leakage means that interactions with concomitant medications must still be carefully considered. Additionally, the ILP procedure itself requires various supportive medications (anesthetics, analgesics, anticoagulants) that can interact with the effects of tasonermin.

The synergistic combination of tasonermin and melphalan is the cornerstone of the ILP treatment approach. Tasonermin selectively damages tumor vasculature, increasing the permeability of tumor blood vessels. This allows melphalan to penetrate deeper into the tumor tissue and achieve much higher intratumoral concentrations than would be possible with melphalan alone. This synergy is the primary rationale for the combined approach and explains the superior response rates compared to melphalan monotherapy.

Major Interactions

Minor Interactions

General anesthetic agents used during the ILP procedure may have additive hemodynamic effects with tasonermin. The anesthesiology team should be informed about the potential for TNF-alpha-mediated hypotension and should be prepared with vasopressors and fluid resuscitation. Opioid analgesics used for post-operative pain management do not have specific interactions with tasonermin but may contribute to hemodynamic changes in the post-operative period.

Corticosteroids, which may be given to manage inflammatory side effects of the ILP procedure, do not diminish the antitumor effects of tasonermin when used at standard anti-inflammatory doses. Prophylactic antiemetics (such as ondansetron) can be safely used to manage post-procedural nausea without affecting BEROMUN's efficacy.

What Is the Correct Dosage of BEROMUN?

BEROMUN dosing is based on limb volume and is strictly determined by the treating surgical oncologist. The standard dose is 3 mg for lower limb perfusion and 4 mg for upper limb perfusion, administered as a single procedure via isolated limb perfusion in combination with melphalan.

Adults

The dosage of BEROMUN is determined by the limb being treated rather than by body weight or body surface area. For isolated limb perfusion of the lower extremity (leg), the recommended dose is 3 mg of tasonermin. For the upper extremity (arm), the recommended dose is 4 mg. These doses have been established through phase II and III clinical trials to provide optimal antitumor efficacy while maintaining acceptable safety within the isolated perfusion circuit.

Children

BEROMUN has not been studied in pediatric patients (under 18 years of age). Soft tissue sarcomas in children are extremely rare, and the experience with isolated limb perfusion in the pediatric population is very limited. Any consideration of using BEROMUN in a pediatric patient would require careful multidisciplinary discussion and would be performed on a compassionate use or off-label basis at specialized centers with pediatric oncology expertise.

Elderly

No specific dose adjustment is required for elderly patients based on age alone. However, older patients are more likely to have comorbidities that may affect eligibility for the ILP procedure, particularly cardiovascular disease, hepatic impairment, or renal impairment. Thorough pre-treatment assessment is essential, and the benefit-risk balance should be carefully evaluated for each patient. In clinical trials, elderly patients experienced similar response rates but had a slightly higher incidence of cardiovascular complications.

Missed Dose

The concept of a missed dose does not apply to BEROMUN in the traditional sense, as it is administered as a single procedure during isolated limb perfusion. If the procedure is postponed or canceled for medical reasons, the treating team will reschedule the ILP at an appropriate time based on the patient's clinical status and the urgency of the tumor situation.

Overdose

There is no specific antidote for tasonermin overdose. In the event of inadvertent overdose during isolated limb perfusion, immediate washout of the perfusion circuit with large volumes of crystalloid solution is the primary intervention. If systemic leakage has occurred, intensive supportive care including vasopressor support, fluid resuscitation, and organ-specific management may be required. The treating team should be prepared for the possibility of severe hemodynamic instability, disseminated intravascular coagulation, and multi-organ dysfunction.

What Are the Side Effects of BEROMUN?

The most common side effects of BEROMUN include fever, chills, nausea, fatigue, local limb reactions (pain, swelling, blistering), and transient liver function abnormalities. Serious complications can include compartment syndrome, cardiovascular events, and infection. Most side effects are related to the ILP procedure and the pharmacological action of TNF-alpha.

Side effects associated with BEROMUN treatment occur through two main mechanisms. First, the local effects within the perfused limb result from the direct action of tasonermin and melphalan on limb tissues. Second, systemic effects can occur even with minimal leakage of TNF-alpha into the general circulation, as the cytokine is extremely potent and activates a wide range of inflammatory pathways.

The severity of side effects is closely related to the degree of systemic leakage during the procedure. Centers experienced in ILP techniques typically achieve very low leakage rates (<5%), which is associated with a lower incidence and severity of systemic adverse effects. This underscores the importance of having the procedure performed at specialized, high-volume centers.

Most side effects occur within the first 48-72 hours after the procedure and are managed in an intensive care or high-dependency setting. The majority of adverse events are transient and resolve within 1-2 weeks, though some local limb complications may take longer to fully resolve.

How Should You Store BEROMUN?

BEROMUN must be stored at -20°C in a freezer. The reconstituted solution must be used immediately or within 24 hours if stored at 2-8°C. As a hospital-only medication, storage is managed entirely by the pharmacy and surgical team.

BEROMUN is supplied as a lyophilized (freeze-dried) powder for reconstitution. The vials must be stored at -20°C (±5°C) in a freezer. The product should be protected from light and kept in its original packaging until ready for use. Under these storage conditions, the shelf life is as specified by the manufacturer on the product label.

Before use, the lyophilized powder is reconstituted with sterile water for injection according to the product's instructions. The reconstituted solution should be clear and colorless to slightly yellow. If the solution is cloudy, discolored, or contains particulate matter, it must not be used. The reconstituted solution should ideally be used immediately, but can be stored for up to 24 hours at 2-8°C if necessary.

As BEROMUN is a hospital-restricted medicine used only during isolated limb perfusion procedures, patients do not need to manage storage themselves. The hospital pharmacy and the surgical oncology team are responsible for proper storage, reconstitution, and quality control of the product. Any unused product or waste material should be disposed of in accordance with local regulations for cytotoxic drugs.

What Does BEROMUN Contain?

Each vial of BEROMUN contains 1 mg of tasonermin (recombinant human TNF-alpha-1a) as the active substance. Excipients include sodium dihydrogen phosphate dihydrate, disodium phosphate dodecahydrate, and human serum albumin as a stabilizer.

The active substance in BEROMUN is tasonermin, which is a recombinant form of human tumor necrosis factor alpha-1a (TNF-alpha-1a). It is produced by recombinant DNA technology using Escherichia coli as the expression system. The protein consists of 157 amino acids and has a molecular weight of approximately 17.4 kDa. It forms a biologically active homotrimer in solution.

The excipients (inactive ingredients) in BEROMUN serve important roles in stabilizing the protein during storage and reconstitution. Sodium dihydrogen phosphate dihydrate and disodium phosphate dodecahydrate act as buffer agents to maintain the pH of the solution within the optimal range for protein stability. Human serum albumin serves as a carrier protein that prevents tasonermin from adsorbing to the vial surface and losing potency.

The solvent provided for reconstitution is sterile water for injection (5 mL). After reconstitution, each milliliter of solution contains 0.2 mg of tasonermin. The solution is then further diluted in the perfusion circuit, which typically has a total volume of several hundred milliliters depending on the limb being treated and the specific perfusion technique used.

BEROMUN does not contain any preservatives, antimicrobial agents, or other additives. It is free from latex and does not contain any animal-derived components other than the human serum albumin used as a stabilizer. Patients with known hypersensitivity to any of the excipients should not receive BEROMUN.